» Articles » PMID: 18022579

Higher Risk of Cytomegalovirus and Aspergillus Infections in Recipients of T Cell-depleted Unrelated Bone Marrow: Analysis of Infectious Complications in Patients Treated with T Cell Depletion Versus Immunosuppressive Therapy to Prevent...

Overview
Date 2007 Nov 21
PMID 18022579
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Serious infections are a major obstacle limiting the usefulness of unrelated donor marrow transplantation. Graft-versus-host disease (GVHD) and its therapy are associated with a high risk of opportunistic infection. In this study, patients were randomized to receive 1 of 2 GVHD prophylaxis strategies, marrow T cell depletion, and cyclosporine (TCD) or methotrexate/cyclosporine (M/C) after transplantation. The patients underwent transplantation between March 1995 and October 2000 as part of a multicenter randomized trial. As a secondary analysis, we analyzed infections in this study cohort. Among the 404 patients who underwent transplantation, a total of 1598 infections were reported. The rates of serious and fatal infections did not differ between the TCD and M/C groups. Bacterial infections accounted for 1/3 of serious infections in each treatment arm. A significantly higher incidence of severe cytomegalovirus (CMV) and life-threatening or fatal aspergillus infections was observed in the patients receiving TCD (CMV, 28% vs 17% [P = .02]; aspergillosis, 16% vs 7% [P < .01]). The only independent risk factor for serious infection was the development of grade III-IV acute GVHD (aGVHD; hazard ratio = 1.41; 95% confidence interval = 1.03-1.91). Strategies to speed immune recovery, even in the absence of GVHD, are needed to overcome the risk of infection after unrelated donor transplantation.

Citing Articles

Infectious complications distribution following CLL1 CAR-T cell therapy for acute myeloid leukemiass.

Xu J, Zhang H, Zhao Y, Zhang X, Guo S, Shi X Cancer Immunol Immunother. 2025; 74(5):149.

PMID: 40088283 DOI: 10.1007/s00262-025-03998-1.


Daily Fungal Cell-Free DNA Testing to Assess Clinical Status during Fungemia.

Young J, Liu X, Porter E, Sweet H, Wang W, Evans A J Fungi (Basel). 2024; 10(7).

PMID: 39057334 PMC: 11278359. DOI: 10.3390/jof10070449.


Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens.

Morrissey C, Kim H, Duong T, Moran E, Alastruey-Izquierdo A, Denning D Med Mycol. 2024; 62(6).

PMID: 38935907 PMC: 11210617. DOI: 10.1093/mmy/myad129.


Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee.

Shahid Z, Etra A, Levine J, Riches M, Baluch A, Hill J Transplant Cell Ther. 2024; 30(5):540.e1-540.e13.

PMID: 38458478 PMC: 11217895. DOI: 10.1016/j.jtct.2024.03.001.


Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective....

Li X, Yang J, Cai Y, Huang C, Xu X, Qiu H Front Immunol. 2023; 14:1252879.

PMID: 37954615 PMC: 10639171. DOI: 10.3389/fimmu.2023.1252879.